| pubmed-article:19545870 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19545870 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:19545870 | lifeskim:mentions | umls-concept:C0000768 | lld:lifeskim |
| pubmed-article:19545870 | lifeskim:mentions | umls-concept:C0023820 | lld:lifeskim |
| pubmed-article:19545870 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:19545870 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19545870 | pubmed:dateCreated | 2009-11-30 | lld:pubmed |
| pubmed-article:19545870 | pubmed:abstractText | Epidemiological evidence supports the use of non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B-100 (apoB), and low-density lipoprotein particles as markers of atherogenic risk. Treatment guidelines also identify these as additional targets of lipid-modifying intervention in patients with elevated triglycerides (TG). Even when TG are only moderately elevated, many patients on statin monotherapy who have achieved targets for low-density lipoprotein cholesterol (LDL-C) fail to reach non-HDL-C treatment goals, and even fewer reach apoB goals. Combination lipid-modifying therapy is therefore indicated for comprehensive lipid management, particularly in patients with type 2 diabetes and metabolic syndrome in whom LDL-C levels are often considered 'optimal'. Of the available options, adding either a niacin, fibrate or omega-3 fatty acids provides greater opportunity to achieve non-HDL-C and apoB targets, given complementary profiles of lipid-modifying activity and supported by evidence from clinical studies. Improvement in lipid control and reduction in atherogenic risk could be anticipated to translate to benefits in clinical outcomes. | lld:pubmed |
| pubmed-article:19545870 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19545870 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19545870 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19545870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19545870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19545870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19545870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19545870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19545870 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19545870 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19545870 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:19545870 | pubmed:issn | 1879-1484 | lld:pubmed |
| pubmed-article:19545870 | pubmed:author | pubmed-author:RosensonRober... | lld:pubmed |
| pubmed-article:19545870 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19545870 | pubmed:volume | 207 | lld:pubmed |
| pubmed-article:19545870 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19545870 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19545870 | pubmed:pagination | 328-35 | lld:pubmed |
| pubmed-article:19545870 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:meshHeading | pubmed-meshheading:19545870... | lld:pubmed |
| pubmed-article:19545870 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19545870 | pubmed:articleTitle | Management of non-high-density lipoprotein abnormalities. | lld:pubmed |
| pubmed-article:19545870 | pubmed:affiliation | Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA. Robert.rosenson@downstate.edu | lld:pubmed |
| pubmed-article:19545870 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19545870 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:19545870 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19545870 | lld:pubmed |
